Defining the clinical course of multiple sclerosis
Vrije Universiteit Amsterdam · Hôpital Purpan · +2 more institutions
Abstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical…
Citation impact
- FWCI
- 117.86
- Percentile
- 100%
- References
- 32
Authors
32Topics & keywords
- Multiple sclerosis
- Clinical trial
- Clinical phenotype
- Disease
- Medicine
- Clinical disease
- Phenotype
- Medical physics
- Peace, Justice and strong institutions
Funding
- NMNational Multiple Sclerosis Society
- ELEli Lilly and Company
- PPfizer
- APAmylin Pharmaceuticals
- GGlaxoSmithKline
- SSanofi
- GSGilead Sciences
- BBiogen
- TPTeva Pharmaceutical Industries
- APAlexion Pharmaceuticals
- CCelgene
- FHF. Hoffmann-La Roche
- CCCleveland Clinic
- NPNovartis Pharmaceuticals Corporation
- UOUniversity of Alabama at Birmingham
- ECEuropean Committee for Treatment and Research in Multiple Sclerosis
- WTWellcome Trust
- IPIronwood Pharmaceuticals, Incorporated
- UOUniversity of Alabama
- MRMyelin Repair Foundation
- UOUniversity of Texas Health Science Center at Houston
- GPGW Pharmaceuticals
- ATAcorda Therapeutics
- PProthena
- GPGlenmark Pharmaceuticals
- NINational Institute for Health and Care Research
- MSMultiple Sclerosis Society
- UOUniversity of Cambridge
- ECEuropean Commission
- BHBayer HealthCare
- WFWolfson Foundation
- NRNational Research Foundation
- EEisai
- MSMultiple Sclerosis International Federation
- SMSchweizerische Multiple Sklerose Gesellschaft
- SPSun Pharma
- SSSerono Symposia International Foundation
- GGrifols
- NINational Institutes of Health
- GGenentech
- ESEMD Serono
- BCBayer Canada
- SGSanofi Genzyme
- CICanadian Institutes of Health Research
- NSNatural Sciences and Engineering Research Council of Canada
- MRMedical Research Council
- NHNational Heart, Lung, and Blood Institute
- NINational Institute of Neurological Disorders and Stroke